PAR-1 contributes to the innate immune response during viral infection.

Coagulation is a host defense system that limits the spread of pathogens. Coagulation proteases, such as thrombin, also activate cells by cleaving PARs. In this study, we analyzed the role of PAR-1 in coxsackievirus B3-induced (CVB3-induced) myocarditis and influenza A infection. CVB3-infected Par1(-/-) mice expressed reduced levels of IFN-β and CXCL10 during the early phase of infection compared with Par1(+/+) mice that resulted in higher viral loads and cardiac injury at day 8 after infection. Inhibition of either tissue factor or thrombin in WT mice also significantly increased CVB3 levels in the heart and cardiac injury compared with controls. BM transplantation experiments demonstrated that PAR-1 in nonhematopoietic cells protected mice from CVB3 infection. Transgenic mice overexpressing PAR-1 in cardiomyocytes had reduced CVB3-induced myocarditis. We found that cooperative signaling between PAR-1 and TLR3 in mouse cardiac fibroblasts enhanced activation of p38 and induction of IFN-β and CXCL10 expression. Par1(-/-) mice also had decreased CXCL10 expression and increased viral levels in the lung after influenza A infection compared with Par1(+/+) mice. Our results indicate that the tissue factor/thrombin/PAR-1 pathway enhances IFN-β expression and contributes to the innate immune response during single-stranded RNA viral infection.

[1]  P. Carmeliet,et al.  PAR1 contributes to influenza A virus pathogenicity in mice. , 2013, The Journal of clinical investigation.

[2]  N. Mackman,et al.  &bgr;-Adrenergic Receptor Stimulation Transactivates Protease-Activated Receptor 1 via Matrix Metalloproteinase 13 in Cardiac Cells , 2012, Circulation.

[3]  H. Fechner,et al.  Alternatively spliced tissue factor and full-length tissue factor protect cardiomyocytes against TNF-α-induced apoptosis. , 2012, Journal of molecular and cellular cardiology.

[4]  W. Ruf,et al.  Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease-activated receptor 2 cofactors that enhance infection. , 2012, Blood.

[5]  Marc P. Bonaca,et al.  Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.

[6]  S. Vogel,et al.  Proteinase-activated receptor 2 activation promotes an anti-inflammatory and alternatively activated phenotype in LPS-stimulated murine macrophages , 2012, Innate immunity.

[7]  E. Lien,et al.  Toll-like receptor 3-elicited MAPK activation induces stabilization of interferon-β mRNA. , 2012, Cytokine.

[8]  D. Johns,et al.  Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. , 2012, The Journal of clinical investigation.

[9]  Giuseppe Ambrosio,et al.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.

[10]  N. Mackman,et al.  Effect of PAR-2 Deficiency in Mice on KC Expression after Intratracheal LPS Administration , 2011, Journal of signal transduction.

[11]  W. Mitzner,et al.  Th2 Regulation of Viral Myocarditis in Mice: Different Roles for TLR3 versus TRIF in Progression to Chronic Disease , 2011, Clinical & developmental immunology.

[12]  A. Norrby-Teglund,et al.  Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. , 2011, Blood.

[13]  C. Esmon,et al.  Innate immunity and coagulation , 2011, Journal of Thrombosis and Haemostasis.

[14]  D. Knight,et al.  Granzyme K Activates Protease-Activated Receptor-1 , 2011, PloS one.

[15]  N. Mackman,et al.  Protease‐activated receptors and myocardial infarction , 2011, IUBMB life.

[16]  S. Felix,et al.  TRIF Is a Critical Survival Factor in Viral Cardiomyopathy , 2011, The Journal of Immunology.

[17]  N. Mackman,et al.  Protease-Activated Receptor 2 Deficiency Reduces Cardiac Ischemia/Reperfusion Injury , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[18]  J. Towbin,et al.  A Role for Toll-like Receptor 3 Variants in Host Susceptibility to Enteroviral Myocarditis and Dilated Cardiomyopathy* , 2010, The Journal of Biological Chemistry.

[19]  Michael R Dores,et al.  Signal transduction by protease‐activated receptors , 2010, British journal of pharmacology.

[20]  A. Fasano,et al.  Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo , 2010, Mucosal Immunology.

[21]  Y. Laumonnier,et al.  Human cytomegalovirus increases HUVEC sensitivity to thrombin and modulates expression of thrombin receptors , 2010, Journal of Thrombosis and Thrombolysis.

[22]  M. Lederman,et al.  Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. , 2010, Blood.

[23]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[24]  S. Riffault,et al.  Protective Role for Protease-Activated Receptor-2 against Influenza Virus Pathogenesis via an IFN-γ-Dependent Pathway1 , 2009, The Journal of Immunology.

[25]  P. Cohen,et al.  Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. , 2009, The Journal of biological chemistry.

[26]  W. Poller,et al.  Regulation of cardiomyocyte full‐length tissue factor expression and microparticle release under inflammatory conditions in vitro , 2009, Journal of thrombosis and haemostasis : JTH.

[27]  Ji-yuan,et al.  CXCL10 Inhibits Viral Replication Through Recruitment of Natural Killer Cells in Coxsackievirus B3-Induced Myocarditis , 2009 .

[28]  K. Preissner,et al.  A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells. , 2009, Blood.

[29]  M. Richer,et al.  Toll-Like Receptor 3 Signaling on Macrophages Is Required for Survival Following Coxsackievirus B4 Infection , 2009, PloS one.

[30]  T. Seya,et al.  Functional evolution of the TICAM‐1 pathway for extrinsic RNA sensing , 2009, Immunological reviews.

[31]  K. Honda,et al.  A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity , 2008, Proceedings of the National Academy of Sciences.

[32]  E. Kroon,et al.  Interferons: Signaling, antiviral and viral evasion , 2008, Immunology Letters.

[33]  M. Hollenberg,et al.  Analysis of Proteinase-activated Receptor 2 and TLR4 Signal Transduction , 2008, Journal of Biological Chemistry.

[34]  R. Lechler,et al.  Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1–dependent leukocyte recruitment in vivo , 2008, The Journal of experimental medicine.

[35]  A. Dörner,et al.  Viral myocarditis and coagulopathy: increased tissue factor expression and plasma thrombogenicity. , 2008, Journal of molecular and cellular cardiology.

[36]  H. Rammensee,et al.  Effective Chemokine Secretion by Dendritic Cells and Expansion of Cross-Presenting CD4−/CD8+ Dendritic Cells Define a Protective Phenotype in the Mouse Model of Coxsackievirus Myocarditis , 2008, Journal of Virology.

[37]  M. Hollenberg,et al.  Role of protease‐activated receptors in inflammatory responses, innate and adaptive immunity , 2008, Journal of leukocyte biology.

[38]  Jorge Cime-Castillo,et al.  Crosstalk between coagulation and inflammation during Dengue virus infection , 2008, Thrombosis and Haemostasis.

[39]  B. McManus,et al.  Ablation of Matrix Metalloproteinase-9 Increases Severity of Viral Myocarditis in Mice , 2008, Circulation.

[40]  E. Turpin,et al.  STAT-1 Signaling in Human Lung Fibroblasts Is Induced by Vanadium Pentoxide through an IFN-β Autocrine Loop1 , 2008, The Journal of Immunology.

[41]  F. Bistoni,et al.  The contribution of PARs to inflammation and immunity to fungi , 2008, Mucosal Immunology.

[42]  M. Steinhoff,et al.  Protease-activated receptors: novel PARtners in innate immunity. , 2007, Trends in immunology.

[43]  T. Luther,et al.  Protease-Activated Receptor-1 Contributes to Cardiac Remodeling and Hypertrophy , 2007, Circulation.

[44]  N. Mackman,et al.  Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[45]  T. Bugge,et al.  Fibrin and fibrinolysis in infection and host defense , 2007, Journal of thrombosis and haemostasis : JTH.

[46]  M. Beck,et al.  Diet-induced obese mice have increased mortality and altered immune responses when infected with influenza virus. , 2007, The Journal of nutrition.

[47]  H. Friedman,et al.  Thrombin enhances herpes simplex virus infection of cells involving protease‐activated receptor 1 , 2007, Journal of thrombosis and haemostasis : JTH.

[48]  A. Hsu,et al.  SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts , 2007, Basic Research in Cardiology.

[49]  M. Halks-Miller,et al.  Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. , 2007, American journal of physiology. Heart and circulatory physiology.

[50]  Mustapha Si-Tahar,et al.  Cutting Edge: Influenza A Virus Activates TLR3-Dependent Inflammatory and RIG-I-Dependent Antiviral Responses in Human Lung Epithelial Cells1 , 2007, The Journal of Immunology.

[51]  Hongmin Sun,et al.  The interaction between pathogens and the host coagulation system. , 2006, Physiology.

[52]  A. Zell,et al.  Ongoing coxsackievirus myocarditis is associated with increased formation and activity of myocardial immunoproteasomes. , 2006, The American journal of pathology.

[53]  K. Conzelmann,et al.  Viruses know it all: new insights into IFN networks. , 2005, Trends in immunology.

[54]  F. Peale,et al.  A monoclonal antibody that inhibits mouse tissue factor function , 2005, Journal of thrombosis and haemostasis : JTH.

[55]  B. Sherry,et al.  Basal and Reovirus-Induced Beta Interferon (IFN-β) and IFN-β-Stimulated Gene Expression Are Cell Type Specific in the Cardiac Protective Response , 2005, Journal of Virology.

[56]  T. Standiford,et al.  IP-10 mediates selective mononuclear cell accumulation and activation in response to intrapulmonary transgenic expression and during adenovirus-induced pulmonary inflammation. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[57]  S. Steinberg The Cardiovascular Actions of Protease-Activated Receptors , 2005, Molecular Pharmacology.

[58]  L. Frati,et al.  p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. , 2004, Blood.

[59]  E. Fish,et al.  Protective Role for Interferon-&bgr; in Coxsackievirus B3 Infection , 2004, Circulation.

[60]  L. Rozek,et al.  Plasminogen Is a Critical Host Pathogenicity Factor for Group A Streptococcal Infection. , 2004 .

[61]  W. Ruf Emerging roles of tissue factor in viral hemorrhagic fever. , 2004, Trends in immunology.

[62]  N. Mackman Role of tissue factor in hemostasis, thrombosis, and vascular development. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[63]  G. Stewart,et al.  Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[64]  P. Jahrling,et al.  Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. , 2003, The Journal of infectious diseases.

[65]  A. Sabri,et al.  Protease-Activated Receptor-1–Mediated DNA Synthesis in Cardiac Fibroblast Is via Epidermal Growth Factor Receptor Transactivation: Distinct PAR-1 Signaling Pathways in Cardiac Fibroblasts and Cardiomyocytes , 2002, Circulation research.

[66]  S. Coughlin Protease-activated Receptors in Vascular Biology , 2001, Thrombosis and Haemostasis.

[67]  K. Klingel,et al.  Cardioselective Infection With Coxsackievirus B3 Requires Intact Type I Interferon Signaling: Implications for Mortality and Early Viral Replication , 2001, Circulation.

[68]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[69]  H. Zhang,et al.  Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. , 2000, Circulation research.

[70]  S. Kawabata,et al.  Evolution and phylogeny of defense molecules associated with innate immunity in horseshoe crab. , 1998, Frontiers in bioscience : a journal and virtual library.

[71]  P. A. Peterson,et al.  Biological Consequences of Thrombin Receptor Deficiency in Mice , 1996, Thrombosis and Haemostasis.

[72]  A. Naldini,et al.  Thrombin modulation of natural killer activity in human peripheral lymphocytes. , 1996, Cellular Immunology.

[73]  J. Hoffmann,et al.  Innate immunity of insects. , 1995, Current opinion in immunology.

[74]  T. Drake,et al.  Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. , 1993, The American journal of pathology.

[75]  N. Mackman,et al.  Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide , 1991, Molecular and cellular biology.

[76]  C. Esmon,et al.  Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[77]  D. Crossman,et al.  The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. , 1990, The Journal of biological chemistry.

[78]  S. Gregory,et al.  Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin , 1989, Molecular and cellular biology.

[79]  C. Gauntt,et al.  Murine natural killer cells limit coxsackievirus B3 replication. , 1987, Journal of immunology.

[80]  P. Hofschneider,et al.  Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[81]  T. Flægstad,et al.  Increased Tissue Thromboplastin Activity in Monocytes of Patients with Meningococcal Infection: Related to an Unfavourable Prognosis , 1983, Thrombosis and Haemostasis.

[82]  Hong Zhou,et al.  Inhibition of clathrin/dynamin-dependent internalization interferes with LPS-mediated TRAM-TRIF-dependent signaling pathway. , 2012, Cellular immunology.

[83]  R. Flavell,et al.  Novel antagonist antibody to TLR3 blocks poly(I:C)-induced inflammation in vivo and in vitro. , 2011, Cellular immunology.

[84]  T. Poll,et al.  Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study , 2010, Critical care.

[85]  B. McManus,et al.  Matrix metalloproteinases in the pathogenesis of viral heart disease. , 2009, Trends in cardiovascular medicine.

[86]  G. Sen,et al.  Interferons and viral infections , 2009, BioFactors.

[87]  M. Halks-Miller,et al.  Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. , 2007, American journal of physiology. Heart and circulatory physiology.

[88]  R. Flavell,et al.  Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. , 2007, American journal of physiology. Heart and circulatory physiology.

[89]  J. Degen,et al.  Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. , 2005, Blood.

[90]  B. Sherry,et al.  Basal and reovirus-induced beta interferon (IFN-beta) and IFN-beta-stimulated gene expression are cell type specific in the cardiac protective response. , 2005, Journal of virology.

[91]  H. Schultheiss,et al.  Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. , 2003, Circulation.

[92]  H. Schultheiss,et al.  Interferon- (cid:1) Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction , 2003 .

[93]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[94]  J. Massagué TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[95]  T. van der Poll,et al.  Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. , 1994, The Journal of clinical investigation.

[96]  T. Drake,et al.  Procoagulant Response of the Endothelium and Monocytes , 1993 .

[97]  H. Redl,et al.  Pathophysiology of Shock, Sepsis, and Organ Failure , 1993, Springer Berlin Heidelberg.

[98]  F. Taylor,et al.  Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. , 1991, Circulatory shock.

[99]  B. Osterud,et al.  Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. , 1983, Thrombosis and haemostasis.